SEARCH

SEARCH BY CITATION

Table S1. Evidence-based Medicine websites search.

Table S2. Treatment of VTE in cancer patients with vitamin K antagonists – Retrospective studies.

Table S3. Treatment of VTE in cancer patients with vitamin K antagonists – Prospective studies.

Table S4. Treatment of VTE in cancer patients with vitamin K antagonists – Control arms of prospective randomized studies.

Table S5. LMWH in the initial treatment of venous thromboembolism – Meta-analyses in general population including cancer patients.

Table S6. Other studies on the treatment of VTE in cancer patients.

Table S7. Thrombolytic therapy.

Table S8. Vena cava filters.

Table S9. Prospective cohorts and randomized trials – long-term use of low-molecular-weight heparins.

Table S10. Meta-analyses.

Table S11. Other studies: idraparinux and duration of anticoagulation.

Table S12. Retrospective study – Treatment of VTE recurrence.

Table S13. Randomized controlled trials – LMWH or UFH vs. placebo or no treatment and LMWH vs. UFH.

Table S14. Meta-analyses: LMWH or UFH vs. placebo or no treatment and LMWH vs. UFH.

Table S15. Randomized controlled trials – Comparison of drugs and dose of LMWH.

Table S16. Randomized controlled trials – Duration of prophylaxis.

Table S17. Extended prophylaxis meta-analysis.

Table S18. Randomized controlled trials: external compression device with intermittent compression device (ICD).

Table S19. Meta-analysis of studies in neurosurgical cancer patients: external compression device.

Table S20. Thromboprophylaxis with UFH vs. LMWH: randomized trials in general medical patients including cancer patients.

Table S21. Thromboprophylaxis with LMWH or fondaparinux: randomized double-blind trials in general medical patients including cancer patients.

Table S22. Prospective studies of primary prophylaxis of VTE in children with Acute Lymphocytic Leukemia (ALL) treated with L-asparaginase.

Table S23. Ambulatory patients treated with chemotherapy.

Table S24. Studies of prophylaxis in patients with myeloma treated with thalidomide or lenalidomide.

Table S25. Meta-analysis: patients with myeloma treated with thalidomide or lenalidomide.

Table S26. Treatment of established VTE in patients with a brain tumor.

Table S27. VTE prophylaxis in cancer patients undergoing neurosurgery.

Table S28. Meta-analyses: VTE prophylaxis in neurosurgical cancer patients.

FilenameFormatSizeDescription
JTH_12070_sm_TableS0-S27.pdf426KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.